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Soluble vonWillebrand factor (VWF) has a low affinity for plate-
let glycoprotein (GP) Ib and needs immobilization and/or high
shear stress to enable binding of its A1 domain to the receptor. The
previously described anti-VWF monoclonal antibody 1C1E7
enhances VWF/GPIb binding and recognizes an epitope in the
amino acids 764–1035 region in the N-terminal DD3 domains. In
this study we demonstrated that the DD3 region negatively modu-
lates the VWF/GPIb-IX-V interaction; (i) deletion of the DD3
region in VWF augmented binding to GPIb, suggesting an inhib-
itory role for this region, (ii) the isolated DD3 region inhibited the
GPIb interaction of a VWF deletion mutant lacking this region,
indicating that intramolecular interactions limit the accessibility of
theA1domain, (iii) using a panel of anti-VWFmonoclonal antibod-
ies, we next showed that the DD3 region is in close proximity with
the A1 domain in soluble VWF but not when VWF was immobi-
lized; (iv) destroying the epitopeof 1C1E7 resulted in amutantVWF
with an increased affinity for GPIb. Our results support amodel of
domain translocation in VWF that allows interaction with GPIb.
The suggested shielding interaction of the A1 domain by the DD3
region then becomes disrupted by VWF immobilization.
The plasma protein vonWillebrand factor (VWF)4 has a central role
in normal primary hemostasis (1). The interaction of VWF with its
platelet receptor glycoprotein (GP) Ib in the GPIb-IX-V complex
mediates platelet adhesion to extracellular matrices exposed at sites of
vascular injury. This interaction is essential for thrombus formation at
sites of high shear stress, as in microarterioles or in stenosed arteries.
Mature VWF comprises a series of multimers that are composed of
homodimers interlinked through disulfide bridges. The mature VWF
subunit consists of four distinct types of internal homology present in
two to three copies in the following order from the N terminus:
D-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK.
Native VWF in solution has an extremely low affinity for GPIb,
suggesting the existence of specific regulatory mechanisms that main-
tain ligand and receptor in the same environment without adverse con-
sequences. The affinity of VWF toward its primary receptor can be
increased by artificial means, such as removal of sialic acid side chains
(2) or the presence of modulators like the bacterial glycopeptide risto-
cetin (3) or the snake venom protein botrocetin (4). In pathophysiolog-
ical conditions, however, binding is induced by immobilization of VWF
or by elevated fluid shear stress, which is likely due to changes in inter-
domain interactions (5).
The VWF A1 domain (amino acids (aa) 1260–1479) contains the
only known GPIb binding site (6). A 39/34-kDa dispase fragment of
human VWF (aa 1243/1244–1481) (7) and the recombinant VWF frag-
ment VCL (aa 1267–1491) (8), both spanning the A1 domain, bind to
platelet GPIb-IX-V in the absence of modulators, in contrast to full-
length VWF. Therefore, it is not unlikely to suppose that the remainder
of VWF, outside the A1 domain, serves as a masking environment,
preventing binding to GPIb-IX-V. Conformational changes in VWF
upon immobilization or upon exposure to shear might relieve this pos-
sible shielding effect of neighboring domains inVWFandmight thereby
reveal the functional binding site in the A1 domain. Thismode of action
is supported by kinetic and crystal studies, which demonstrated a higher
binding affinity of the isolated A1 domain for GPIb-IX-V compared
with full-length VWF (9–11). Moreover, these crystal studies confirm
that conformational changes in both GPIb and in the A1 domain are
required for their mutual interaction.
The A1 domain contains a typical /-fold that is delimited by a
single disulfide bridge (aa 1272–1456) (12). The N-terminal region in
theA1 domain (aa 1260–1271), flanking the disulfide bridge,modulates
the A1/GPIb interaction; (i) crystal studies reveal a displacement of
this flanking region upon binding to GPIb (10, 11); (ii) naturally occur-
ring mutations in this region have been reported to induce von Will-
ebrand disease (VWD) type 2B phenotype, characterized by an
increased affinity of VWF for GPIb (13); (iii) Ala substitution mutants
in this region show an increased affinity for GPIb (14).
As mentioned before, it is suggested that neighboring domains in
VWF might impede the accessibility of the GPIb binding region. We
have previously described a monoclonal antibody (moAb), 1C1E7,
directed against the aa 764–1035 region in the N-terminal DD3
domains of VWF (15). Although this moAb interacts with a region
distinct from the VWF A1 domain, it induces von Willebrand disease-
type 2B-like alterations (16). This would suggest that the binding region
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of 1C1E7 in VWF might have a modulatory role for the VWF/GPIb
interaction and could be a shielding region for the GPIb binding
domain. The objectives of this study were to obtain evidence for the
functionality of the DD3 region in VWF for GPIb binding using dele-
tion mutants, constructed VWF chimeras, and recombinant 1C1E7 as
tools.
EXPERIMENTAL PROCEDURES
Materials—Different moAbs against VWF were described previ-
ously. moAb 82D6A3 binds to the VWF A3 domain and inhibits VWF
binding to collagen types I, III, and IV (17), andmoAb 1C1E7 recognizes
the N-terminal part of VWF (aa 764–1035) (15). moAbs 724, 701, and
418 were kind gifts of Dr. J. P. Girma (INSERM U143, le Kremlin-Biceˆ-
tre, Paris, France). moAbs 724 and 701 recognize the VWF A1 domain
(18, 19), whereas moAb 418 interacts with the first 106 aa in mature
VWF (20). VWFwas purchased from the RedCross (Brussels, Belgium).
moAbs or VWF were biotinylated using EZ-link Sulfo-NHS-SS-Biotin
(Perbio, Helsingberg, Sweden).
Pooled plasmawas prepared from the plasma of 25 healthy volunteers
(21). The vector pSV2-dhfr (22) was obtained fromAmerican Type Cell
Culture (Manassas, VA). Restriction endonucleaseswere fromMBI Fer-
mentas (Vilnius, Lithuania).
Numbering of the aa sequence of VWF or the nucleotide sequence of
the VWF gene starts with, respectively, the initiator methionine or the
start codon as the1 position. Recombinant VWF/DA3 (aa 1–1874),
VWF/DD3 (aa 1–1247), and VWF/A1-CK (1260–2813) were
expressed and purified as described before (23). For clarity, we renamed
VWF/DA3 and VWF/A1-CK as plusDD3 and DD3, respectively. A
representation of VWF, its fragments, and the binding sites of the
moAbs is shown in Fig. 1.
Construction and Expression of 1C1E7 Single-chain Variable
Fragment—Total cell RNA was extracted from 1C1E7-expressing
hybridoma cells using the RNeasy mini kit (Qiagen, Venlo, The Neth-
erlands) and was reverse-transcribed in the ThermoScript reverse tran-
scription-PCR system (Invitrogen) using oligo(dT)20 primers.
The N-terminal sequence of the heavy and light chain of 1C1E7 was
determined by TopLab (Martinsried, Germany). Based on these data,
degenerate sense primers were designed for the heavy and the light
chain variable regions (VH and VL, respectively), and framework-spe-
cific antisense primers were used in the subsequent PCR reactions (24,
25). Amplification of VH was performed using Pfu Turbo DNA polym-
erase (Stratagene, La Jolla, CA), and the resulting PCR product was
ligated in the pCR®-Blunt vector (Invitrogen). VL was amplified with
Platinum Taq DNA polymerase (Invitrogen), and the resulting PCR
product was ligated in the pCR®2.1-TOPO® vector (Invitrogen). For the
construction of the 1C1E7 single-chain variable fragment (scFv), both
VH and VL were extended such that the following splice overlapping
extension PCR resulted in a VH-(G4S)3-VL scFv coding sequence. This
PCR product was ligated in the pSecTag/FRT/V5-His vector
(Invitrogen).
The 1C1E7 scFv was expressed in Escherichia coli as a His-tag fusion
protein. Briefly, NcoI andXhoI restriction sites were added to the 3 and
5 ends, respectively, by PCR using sequence-specific primers. The
1C1E7 scFv DNA was cloned in the pET26 vector (Stratagene) using
theNcoI andXhoI restriction sites. BL-21 E. coliwere transformedwith
the construct and were induced for 2 h with 0.5 M isopropyl--D-galac-
toside. The bacteria were harvested (10,000  g for 10 min), and cell
proteins from the pellet were extracted with the BugBuster protein
extraction reagent (Novagen, Merck). 1C1E7 scFv was expressed as
inclusion bodies. To refold the scFv, inclusion bodies were dissolved in
IB buffer (6 M guanidine-HCl, 1.5 M urea, 0.6 mM reduced glutathione,
0.3 mM oxidized glutathione in phosphate-buffered saline, PBS) (26).
The solubilized proteins were subsequently dialyzed against a series of
urea solutions (8, 6, 4, and 2 M overnight (ON) at 4 °C) and, finally
against PBS.
Ristocetin- and Botrocetin-induced Binding of VWF, DD3,
plusDD3, or Recombinant VWF to a Recombinant GPIb Fragment (aa
1–289)—The ristocetin- and botrocetin-induced binding of VWF,
DD3, plusDD3, or recombinant VWF (see later) to a GPIb frag-
ment was performed as previously described (21). Briefly, microtiter
plates were coated ON at 4 °C with anti-GPIbmoAb 2D4 (5 g/ml in
PBS) and blocked with Tris-buffered Saline (TBS) containing 3% milk
powder. A recombinant N-terminal, VWF binding GPIb fragment (aa
1–289) (rGPIb) was expressed in Chinese hamster ovary cells and
FIGURE1.Schematic representationof amature
VWF subunit and the VWF deletion mutants
used in this study. Binding regions of the anti-
VWF moAbs are indicated.
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purified as described (27). Wells were incubated for 1.5 h at 37 °C with
rGPIb (1 g/ml in TBS, 0.1% Tween 20) and incubated for 1.5 h at
37 °C with a dilution series of ristocetin (abp, New York, NY) or botro-
cetin purified from crude Bothrops jararaca venom (Sigma) (28) in the
presence of a constant amount of purified VWF, DD3, plusDD3, or
recombinant VWF (0.5 g/ml) and in the absence or presence of 12
g/ml 1C1E7 IgG. Bound VWF, DD3, plusDD3, or recombinant
VWF was detected for 45 min at room temperature (RT) with a 1/3000
dilution of anti-VWF polyclonal antibodies labeled with horseradish
peroxidase (anti-VWF-Ig-horseradish peroxidase, Dako, Glostrup,
Denmark). Visualization was obtained with H2O2 and ortho-phe-
nylenediamine (Sigma), and the coloring reaction was stopped with 4 M
H2SO4, after which the absorbance was determined at 490 nm.
Platelet Agglutination—Agglutination studies were performed in an
Elvi-840 dual channel aggregometer (Pabish, Brussels, Belgium) with
constant stirring at 1000 rpm at 37 °C.
For the agglutination experiments using 1C1E7 scFv, blood was
drawn fromhealthy volunteers on trisodium citrate, pH 7.5 (0.11M, 10:1
v/v), and centrifuged at 180  g for 10 min to obtain platelet-rich
plasma. Platelet-rich plasma was incubated for 3 min with buffer and
with 1C1E7 scFv or IgG, after which agglutination was induced by the
addition of ristocetin.
For the agglutination experiments using the VWF fragments, blood
was collected on acid citrate dextrose (0.085M trisodiumcitrate, 0.065M
citric acid, 0.110 M glucose, pH 4.5) (10:1.5 v/v). Platelets were washed
twice and resuspended in PBS containing 1mg/ml glucose and 1mg/ml
bovine serum albumin. A final platelet concentration of 200,000 plate-
lets/l was used.DD3, plusDD3, orVWF/DD3were added to a final
concentration of 10 g/ml, and the mixture was incubated for 3 min,
after which agglutination was induced by the addition of ristocetin.
Construction of Expression Plasmid for Chimeric Porcine/Human
Recombinant VWF—An expression plasmid for a chimeric porcine/
human recombinant VWF in which the aa 786–960 region of the
human sequence was exchanged by the corresponding porcine
sequence was constructed. This recombinant VWF construct is further
referred to as VWF(aa786–960)PIG.
Briefly, the expression vector pNUT-VWF cas (29) was digested with
the restriction endonuclease BglII, and the resulting 4.7-kilobase frag-
ment was ligated subsequently in the unique BglII site of the vector
pSV2-dhfr to give the vector pSV2-pNUT.
RNA was isolated from a porcine umbilical cord using the mRNA
isolation kit (Roche Molecular Biochemicals), and cDNA was prepared
with the ThermoscriptTM reverse transcription-PCR system (Invitro-
gen) using the sequence specific primer RP3 (5-CGC AGG TTC CTC
TCC TCG CAG TTC-3, nucleotides 3384–3408). cDNA was ampli-
fied by PCR using the sense primer P5 (5-CGC AGC AAG AGG AGT
CTGAGCTGCCGGCCCCCCATG-3, nucleotides 2279–2314) and
the antisense primer RP3. The PCR product was ligated in the vector
PCR4 Blunt-TOPO vector (Invitrogen). A unique EagI restriction site at
position 2875 was introduced by PCR using the sense primer P5 and the
point-mutated antisense primer P6.2 (5-GAT GAA CCG GCC GGA
TTC CAC3, nucleotide 2867–2887). The PCR product was cloned in
the pBAD-TOPOTA vector (Invitrogen) to give the vector pBAD-PIG.
Subsequently, the XhoI-EagI fragment of the vector pBAD-PIG was
ligated in XhoI-EagI-digested pSV2-pNUT to give the vector pSV2-
pNUT-PIG. The vector pSV2-pNUT-PIG was digested with EcoRI and
BglII. The resulting 4.7-kilobase fragment was exchanged by the corre-
sponding sequence of pNUT-VWF cas to give the final expression vec-
tor pNUT-VWF PIG.
Construction of Expression Plasmids for VWF Point or Double
Mutants—Expression plasmids for human VWF or for VWF(aa786–
960)PIG containing K968S, K991Q or S1009G,N1011S mutations were
constructed starting from the plasmid pSV2-pNUT or pSV2-pNUT-
PIG, respectively. Using the QuikChange XL site-directed mutagenesis
kit (Stratagene) and specific primers, the desired mutations were intro-
duced. The resulting vectors were digested with EcoRI and BglII, and
the resulting 4.7-kilobase fragment was exchanged by the correspond-
ing sequence of pNUT-VWF cas or pNUT-VWF PIG as described
above to obtain expression plasmids for full-length VWF.
Expression of Recombinant VWF—VWFwas transiently expressed in
COS-7 cells (30) or stably expressed in baby hamster kidney cells over-
expressing furin (BHK-fur) as described before (6). The VWF:Ag level
was determined in a sandwich immunoassay as previously described
(21).
Binding of VWF tomoAb1C1E7—96-Wellmicrotiter plates (Greiner,
Frickenhausen, Germany) were coated ON at 4 °C with moAb 1C1E7
(10 g/ml in PBS), blocked for 2 h at RT with TBS containing 3% milk
powder, and incubated for 2 h at 37 °C with a dilution series of VWF
expression medium in TBS containing 0.3% milk powder. Bound VWF
was detected as described above.
Binding of VWF to Human Collagen Type III—96-Well microtiter
plates were coated ON at 4 °C with 25 g/ml human collagen type III
(Sigma) in PBS. Wells were blocked with PBS containing 3% milk pow-
der and incubatedwith a dilution series of purified recombinantVWF in
PBS containing 0.3% milk powder. Bound VWF was detected as
described above (24).
Multimeric Analysis—The multimeric pattern of VWF was deter-
mined essentially as described (31). Briefly, 0.08 g of VWF was sepa-
rated on SDS 0.65% Seakem HGT, agarose gel (Cambrex, Bio Science
Rockland, Inc., ME). Gels were fixed on Gelbond (Cambrex), and VWF
was immunodetected using anti-VWF-Ig labeled with alkaline phos-
phatase (32) and further revelation with the AP conjugate substrate kit
(Bio-Rad).
Cross-blocking Analysis for Antibody Binding to Immobilized VWF—
96-Well microtiter plates were coated ON at 4 °C with VWF (10 g/ml
in PBS) and blocked for 2 h at RT with TBS containing 3%milk powder.
Wells were incubated for 1 h at 37 °C with biotinylated moAb 418
(b-418) at its half-maximal binding concentration (0.15 g/ml) in the
presence of the competing moAbs 701, 724, 418, or 82D6A3 (15g/ml)
using TBS containing 0.3%milk powder as buffer. Residual bound b-418
was detected for 45 min at RT with peroxidase-labeled streptavidin
(1/10000 in TBS containing 0.3% milk powder). Visualization was per-
formed as described above.
Cross-blocking Analysis for Antibody Binding to “Soluble” VWF—96-
Wellmicrotiter plates were coatedwithmoAb 418 (2g/ml in PBS) and
blocked for 2 h at RTwith TBS containing 3%milk powder. Biotinylated
VWF (b-VWF, 6 g/ml) was preincubated with one of the anti-VWF
moAbs (0.5–60 g/ml) for 1 h at 37 °C after which this solution was
transferred to the coated wells. After a further incubation of 30 min at
37 °C, residual bound b-VWF was detected with peroxidase-labeled
streptavidin as described above.
Statistics—In this study means and S.E. are shown. Statistical signif-
icance of differences between means was evaluated using Student’s t
test.
RESULTS
Functionality of VWF Lacking the DD3 Region—It has been sug-
gested that the remainder of VWF outside the A1 domain might shield
the GPIb binding region. However, the exact mechanism of this
Modulation of VWF/GPIb-IX-V Interaction
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shielding has not been elucidated yet. The anti-VWF moAb 1C1E7
interacts with the aa 764–1035 region in the N-terminal DD3 domains
and modulates the binding of VWF to GPIb. This would suggest a
functional role of the DD3 region in the binding of the A1 domain to its
receptor. Therefore, we decided to study this putative modulatory role
using VWF constructs lacking the DD3 region.
Recombinant DD3 (aa 1260–1874) is a dimer composed of two
VWF monomers lacking the DD3 region but still contains the N-ter-
minal flanking region of the VWF A1 domain. We verified the ristoce-
tin- and botrocetin-induced binding of this construct to a recombinant
GPIb fragment and compared its affinity to that of recombinant
plusDD3 (aa 1–1874). This construct is a dimer as well but lacks the
C-terminal D4-B1-B2-B3-C1-C2-CK regions.
In the presence of ristocetin as amodulator,DD3 interacted stron-
ger with rGPIb compared with plusDD3 (Fig. 2A). Similar results
were obtained with botrocetin (Fig. 2B). These results suggest that the
DD3 region has an inhibitory effect on the interaction of theA1domain
with GPIb. The addition of 1C1E7 to plusDD3 increased ristocetin-
induced binding to rGPIb to the level ofDD3while not affecting the
GPIb interaction of DD3 (Fig. 2A). This suggests that the observed
effects are likely not due to a different affinity of the deletionmutants for
the modulators used in the assay.
We further identified the inhibitory role exhibited by theDD3 region
in VWF/GPIb interaction in platelet agglutination experiments.
Dimeric constructs were used because previous studies demonstrated
the necessity of the use of at least dimeric molecules for sustaining
platelet aggregation (33). The threshold dose needed for ristocetin-in-
duced agglutination of washed platelets was lower for DD3 than for
plusDD3 (Fig. 3A), also demonstrating the inhibitory effect of theDD3
region on the interaction of VWF with GPIb.
In line with this, VWF/DD3 inhibited the ristocetin-induced agglu-
tination supported by DD3 while having no effect on the agglutina-
tion supported by plusDD3 (Fig. 3B). These results show that the lack of
inhibition by deletion of theDD3 region inDD3 could be reverted by
external addition of these isolated DD3 domains.
These experiments demonstrate the functionality of the DD3 region
in the interaction of VWF with GPIb, strongly suggesting that this
region shields the GPIb binding site in VWF, restricting its accessibil-
ity and preventing spontaneous VWF binding to platelets.
EpitopeMapping of moAb 1C1E7—To discover residues in the DD3
region that would be responsible for its inhibitory effect, we identified
the binding region of 1C1E7 in VWF. Previous studies demonstrated
that 1C1E7 interacted with a tryptic fragment comprising the aa 764–
1035 sequence in VWF, which is located in the DD3 region (15). The
location of the epitope was further corroborated by the fact that 1C1E7
failed to interact with DD3 but recognized the isolated DD3 region
(data not shown). Because 1C1E7 does interact with VWF in Western
blot, this moAb probably recognizes a linear epitope. Therefore, the
FIGURE 3. Ristocetin-induced platelet aggluti-
nation. A, washed platelets (200,000 platelets/l)
were incubated with 10 g/ml DD3 (1) or
plusDD3 (2 and3) after which agglutination was
induced by the addition of 0.1 mg/ml ristocetin (1
and 3) or 0.2 mg/ml ristocetin (2). Results are rep-
resentative of three independent experiments. B,
washed platelets (200,000 platelets/l) were incu-
bated with 10 g/ml DD3 or plusDD3 in the
presence of 10 g/ml VWF/DD3, after which
agglutination was induced by the addition of a
threshold dose of ristocetin (0.1 and 0.2 mg/ml,
respectively). The percentage inhibition is shown
(mean S.E., n 3). As the 100%value, agglutina-
tion in the absence of VWF/DD3 was chosen.
FIGURE 2. Ristocetin- and botrocetin-induced
binding of VWF(fragments) to rGPIb. Micro-
titer plates were coated with anti-GPIb moAb
2D4 and incubated with rGPIb. Wells were incu-
bated with a constant amount of DD3 (filled
bars) or plusDD3 (open bars) in the presence or
absence of 1C1E7 IgG (12 g/ml) and in the pres-
ence of ristocetin (A) or botrocetin (B) at the indi-
cated amounts. Bound VWF was detected
(mean S.E., n 3). NS, not significant.
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FIGURE 4. Epitopemapping of 1C1E7. A, binding
of recombinant WT and mutant VWF to 1C1E7.
Microtiter plates were coated with 1C1E7 or anti-
VWF-Ig and incubatedwith expressionmediumof
recombinant VWF. Bound VWF was detected with
anti-VWF-Ig-horseradish peroxidase. The ratio of
the A490 nm values for the 1C1E7 binding on the
values for the anti-VWF-Ig are shown in percent-
ages (mean S.E., n 3). B, alignment of the pri-
mary sequence of human, canine, porcine, and
murine VWF in the aa 764–1035 region. Sequence
alignment of human (Medline submissionnumber
NP_000543), canine (Q28295), porcine (Q28833),
and murine (NM_017708) VWF. The aa 786–961
fragment, which was exchanged in the chimeric
construct, is delineated. Residues between aa
961–1035 that are different between human and
porcine, canine, or murine VWF are marked with
boxes. The residues that are different between
human and both porcine andmurine VWF but are
similar between human and canine VWF are
shaded in gray.
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cross-reactivity of 1C1E7 with VWF of different species was verified to
determine if differences in the primary structure of VWF have an effect
on the binding of 1C1E7.
1C1E7 failed to recognize porcine plasma VWF but was still able to
interact with canine VWF (data not shown). This suggests that some of
the 35 residues in the aa 764–1035 region of human VWF that are not
shared with the porcine VWF sequence might maintain the epitope of
1C1E7. To identify these residues, a chimeric recombinant VWF
(VWF(aa786–960)PIG) in which the aa 786–960 region of the human
sequence was exchanged by the corresponding porcine sequence was
constructed. For cloning reasons, only this part of the N-terminal aa
764–1035 region in human VWF was exchanged. This construct, con-
taining 23 residues differing from the human sequence, was transiently
expressed in COS-7 cells, and the interaction with 1C1E7 was deter-
mined. 1C1E7 still interacted with VWF(aa786–960)PIG (Fig. 4A), sug-
gesting that the aa 961–1035 region in VWF probably maintains the
epitope of this moAb. Further comparison of the primary sequence of
human VWF in this region with sequences of porcine, canine, and
murineVWFhighlighted residues Lys-968, Lys-991, Ser-1009, andAsn-
1011 as possible candidates for maintaining the epitope of 1C1E7 (Fig.
4B). These residues are different between human and both porcine and
murine VWF but are similar between the human and canine protein.
VWF mutants in which these residues were exchanged for the porcine
analogues were constructed and transiently expressed in COS-7 cells.
1C1E7 bound as strongly with the K991Q and S1009G, N1011S mutant
as to WT VWF, suggesting that these residues are not important for
maintaining the epitope. However, binding was completely abolished
for the K968S point mutant, identifying this residue as critical for the
interaction of 1C1E7 (Fig. 4A).
Functionality of Chimeric Recombinant VWF—In a next step the ris-
tocetin-induced binding of the recombinant full-length WT VWF and
chimeric constructs to GPIb was measured to verify if altering the
structure in the DD3 region might influence this interaction. Recom-
binantWTVWF, VWF(aa786–960)PIG, and VWF(aa786–960)PIG, in
which a K968S point mutation was inserted (VWF(aa786–960)PIG-
K968S), were expressed in BHK-fur (baby hamster kidney cells overex-
pressing furin) cells. The multimeric pattern of both mutants was sim-
ilar to WT VWF with at least 16 detectable multimer bands (Fig. 5A).
Binding characteristics of the mutants to anti-VWF moAbs 418,
82D6A3, 701, and 724 was similar to WT VWF (data not shown), sug-
gesting a similar overall structural fold.
Next, the functional effects of the exchange of several residues in the
DD3 regionwas verified. The interactionwith fibrillar collagenwas not
statistically different formutant VWF as comparedwith theWT, result-
ing in a VWF:collagen binding assay of 1.09  0.06 and 1.10  0.07
units/ml for VWF(aa786–960)PIG (p 0.28, n 3) and VWF(aa786–
960)PIG-K968S (p  0.25, n  3), respectively, using WT VWF as a
reference (Fig. 5B).
VWF(aa786–960)PIG and VWF(aa786–960)PIG-K968S bound
comparably to rGPIb in the presence of 0.4 mg/ml ristocetin (Fig. 5C).
However, at submaximal doses of ristocetin, VWF(aa786–960)PIG-
K968S showed a small but significant increase in binding comparedwith
VWF(aa786–960)PIG andWT. These results suggest that altering res-
idues in the DD3 region and, more specifically the binding region of
1C1E7, influences the binding affinity of VWF for GPIb.
Cross-blocking Studies—Next, the structural proximity of the DD3
region with the A1 domain in immobilized VWF and in soluble VWF
was verified by analyzing whether binding of moAb 418 (interacting
with the DD3 region) could be blocked by moAbs 701 and 724 (both
interacting with the A1 domain). This would give us the opportunity to
gather information on the structural changes in VWF upon immobili-
zation. As a negative control, moAb 82D6A3 (interacting with the A3
domain) was used. Two different enzyme-linked immunosorbent assay
set-ups were developed, (i) cross-blocking of binding of b-418 to immo-
bilizedVWFby unlabeledmoAbs and (ii) the inhibition of the capture of
b-VWF to immobilized moAb 418 by the unlabeled moAbs. Previous
data demonstrated that biotinylation of VWFhad no effect on the inter-
action with fibrillar collagen or GPIb, which would suggest that the
FIGURE 5. Functionality of chimeric constructs.
A, VWF multimer analysis. Samples of WT VWF (1),
VWF(aa786–960)PIG (2), and VWF(aa786–
960)PIG-K968S (3) were analyzed by SDS-0.65%
agarose gel electrophoresis and detected with
anti-VWF-Ig labeled with alkaline phosphatase. B,
collagen binding assay. Microtiter plates were
coated with human collagen type III and incu-
bated with a dilution series of WT VWF (f),
VWF(aa786–960)PIG (F), and VWF(aa786–
960)PIG-K968S (Œ), after which bound VWF was
detected (mean  S.E., n  3). C, ristocetin-in-
duced binding of VWF to rGPIb. Microtiter plates
were coated with anti-GPIbmoAb 2D4 and incu-
bated with rGPIb. Wells were incubated with WT
VWF (open bars), VWF(aa786–960)PIG (filled bars),
and VWF(aa786–960)PIG-K968S (gray bars) (0.5
g/ml) in the presence of ristocetin at the indi-
cated amounts. Bound VWF was detected
(mean S.E., n 3). NS, not significant.
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conformation of VWF is not altered upon biotinylation (34). When
VWF was immobilized, no measurable inhibition of the binding of
b-418 was observed by any of the moAbs except with unlabeled 418 as
the positive control (Fig. 6, open bars), although all moAbs were able to
interact with immobilized VWF (data not shown). In contrast, moAbs
701 and 724 did compete with moAb 418 for the binding to soluble
b-VWF, whereas moAb 82D6A3 had again no effect (Fig. 6, filled bars).
This would suggest that in solution the A1 domain and the DD3
region are in close proximity sincemoAbs interactingwith these regions
cross-block each other. However, when VWFwas immobilized, moAbs
interacting with the A1 domain failed to block binding of moAb 418
interacting with the DD3 region, suggesting that these regions are now
more distant from each other.
Construction and Expression of 1C1E7 scFv—To further characterize
the VWF-activating potency of the moAb 1C1E7, the scFv was
expressed as aHis-tagged fusion protein in E. coli. 1C1E7 scFv increased
ristocetin-induced platelet aggregation, similarly to 1C1E7 IgG (Fig.
7A), providing evidence that the construction was correct. Moreover,
1C1E7 scFv inhibited binding of the IgG to VWF, suggesting a same
interaction site in VWF (data not shown). Comparison of the primary
sequence of the complimentarity determining region 3 of the 1C1E7
heavy chain revealed a strong similarity with the N-terminal flanking
region of the VWF A1 domain (Fig. 7B). As mentioned before, there is
good evidence that this N-terminal flanking regionmodulates the bind-
ing of VWF to GPIb. Based on our observation, we hypothesized that
1C1E7 might be able to mimic this region of the A1 domain. Because
1C1E7 does bind to the DD3 region in VWF, the N-terminal flanking
region of the A1 domain might have similar binding characteristics.
This putative interaction of the A1 domain with the DD3 region could
modulate the VWF binding to GPIb.
DISCUSSION
Human VWF in solution does not interact with its platelet receptor
GPIb-IX-V under normal conditions. Binding, however, is induced by
immobilization of VWF or by exposure to shear. These observations
suggest that the affinity toward GPIb-IX-V is regulated by conforma-
tional changes in VWF that are induced by shear and/or immobilization
and lead to exposure of functional sites.
In vitro, binding of VWF to GPIb-IX-V can be provided by modula-
tors such as ristocetin or botrocetin. Although in these conditions bind-
ing is inducedrather artificially, it hasbeendemonstrated that ristocetin-
dependent interactions quite closely correlate with the physiological
shear-dependent situation (35).
We have previously identified the moAb 1C1E7 (15) which interacts
with the aa 764–1035 region in the N-terminal DD3 domains in VWF,
increases the affinity of VWF for GPIb, and hence, induces von Will-
ebrand disease type 2B alterations, although it does not bind near the
GPIb-IX-V binding site (16). This would suggest amodulatory effect for
the binding region of 1C1E7 in VWF on the GPIb interaction. There-
fore, the goal of this study was to determine the functional role of the
DD3 region in binding of VWF to GPIb-IX-V.
Deletion of the DD3 region in VWF resulted in a higher affinity for
GPIb as demonstrated in an enzyme-linked immunosorbent assay sys-
tem; the dimeric deletion mutant DD3, lacking the DD3 region,
showed an increased ristocetin- and botrocetin-induced interaction
with a recombinant GPIb fragment compared with the dimeric dele-
tion mutant plusDD3, which lacks the C-terminal region in VWF. The
addition of 1C1E7 IgG to plusDD3 increased the ristocetin-induced
binding to rGPIb, now equaling the binding of DD3. This confirms
again the modulatory effect of 1C1E7 on the VWF/GPIb interaction
but in addition proves that the observed difference in affinity of both
deletion mutants for GPIb is not due to a different affinity for ristoce-
tin. These results were confirmed in a platelet agglutination assay; the
threshold dose of ristocetin needed to induce agglutination of washed
platelets was lower in the presence of DD3 as compared with
plusDD3. Moreover, at lower platelet concentrations, DD3 was able
to sustain spontaneous platelet agglutination in contrast to plusDD3
(data not shown). All together, these data strongly suggest that theDD3
regionmay act as an inhibitory region, shielding theA1 domain inVWF.
Our data further confirm and extend previous studies that demon-
strated the putative shielding of the GPIb binding site in the A1 domain
by the N-terminal flanking regions of the A1 domain (aa 1260–1271)
and the C-terminal region of the D3 region (aa 1204–1259). (i) Peptides
derived from these regions inhibited ristocetin-induced binding of puri-
fied VWF to human platelets (36), (ii) stepwise N-terminal deletions in
the aa 1204–1271 region of a recombinant VWF fragment comprising
the A1 domain (aa 1204–1496) resulted in stepwise increased ristoce-
tin-induced binding to human platelets (37); (iii) Ala mutations in the
N-terminal flanking region of the A1 domain (aa 1260–1271) in full-
length VWF resulted in an increased ristocetin-induced binding to
human platelets (14); (iv) deletions in the aa 1222–1271 region in full-
FIGURE 6.Cross-blocking studies; inhibition of the binding of b-418 to immobilized
VWForb-VWF to immobilizedmoAb418byanti-VWFmoAbs.Microtiter plateswere
coated with VWF (open bars) or with moAb 418 (filled bars) and incubated with b-418 or
b-VWF, respectively, in the presence of the anti-VWF moAbs 82D6A3, 418, 701, or 724.
Residual bound b-418 or b-VWF was detected. Percentage inhibition is shown (mean
S.E.,n 3). As a 100% reference, thebindingof b-418 to immobilizedVWFor thebinding
of b-VWF to immobilized 418 was chosen.
FIGURE 7. Functionality of 1C1E7 scFv. A, stimulating effect of 1C1E7 scFv on platelet
aggregation in platelet-rich plasma. Platelet-rich plasma was incubated with PBS buffer
(1), 1C1E7 scFv refolded from inclusion bodies (20 g/ml) (2), or 25 g/ml 1C1E7 IgG
(3), after which a subthreshold dose of ristocetin (0.2 mg/ml) was added. Results are
representative of three independent experiments. B, alignment of the primary sequence
of the N-terminal flanking region of the human A1 domain and the complimentarity
determining region 3 of the 1C1E7 heavy chain.
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length VWF in which an additional R1308A mutation was added
resulted in an increased ristocetin-induced or even spontaneous bind-
ing to human platelets when compared with the R1308A VWF point
mutant (38); (v) specific O-linked glycosylation in the aa 1248–1256
region negatively modulated the binding to human platelets as demon-
strated using glycosylphosphatidylinositol COS-7 cell-anchored FLAG-
tagged VWF A1 domains (39).
To further identify the exact residues within VWF important for the
binding region of 1C1E7, we took advantage of the observation that
1C1E7 does not interact with porcine VWF. To confirm the putative
role of the deviating residues in human versus pig VWF in maintaining
the epitope of 1C1E7, a chimeric porcine/humanVWFwas constructed
in which the aa 786–960 region of human VWF was exchanged by the
corresponding porcine sequence. In the resulting recombinant protein,
VWF(aa786–960)PIG, 22 of the possibly important residues were
mutated. Compared with the published sequence, an extra mutation
was inserted (P812L); however, in line with previous studies (40), this is
probably a result of strain specificity, because sequencing of different
cDNA clones resulted in the identification of the identical substitution.
VWF(aa786–960)PIG, however, bound as good to 1C1E7 as did WT
VWF, suggesting that the remaining aa 961–1035 region in VWF prob-
ablymaintains the epitope of thismoAb. Furthermutagenesis of the rest
of the differing residues identified Lys-968, located in the VWF D3
domain, as essential for the binding ofmoAb 1C1E7. As yet, this residue
has not been linkedwith a functional deficiency of VWF. The ristocetin-
induced interaction with rGPIb of VWF(aa786–960)PIG containing
an additional K968S mutation was slightly but significantly increased at
submaximal doses of this modulator compared withWT VWF. Similar
results were obtained in platelet agglutination studies (data not shown);
in the presence of VWF(aa786–960)PIG and VWF(aa786–960)PIG-
K968S, lower doses of ristocetin were needed to induce agglutination
compared withWTVWF. These results would suggest that this residue
and/or the surrounding region might be important for modulating the
interaction of VWF with GPIb. However, additional mutagenesis
studies are needed to further confirm this.
VWF/DD3 blocks both spontaneous and ristocetin-induced platelet
agglutination in the presence ofDD3. Similarly, VWF/DD3 inhibited
the spontaneous agglutination supported by DD3 (data not shown).
This is in line with our hypothesis that in solution the DD3 region
interacts with structures in DD3 and that these intramolecular inter-
actions in VWF shield the A1 domain from interacting with GPIb.
It is known that immobilization of VWF is a prerequisite for platelet
adhesion at high shear stress, probably due to conformational changes
(41).However, the exact nature of these conformational changes has not
been elucidated yet (42).
To further substantiate the idea that DD3 would interact with A1 in
VWF in solution and no longer when immobilized/sheared, we looked
to whether moAbs against the respective domains would block each
other’s binding or not under those conditions when VWFwas immobi-
lized on a polystyrene surface, as it is known that this allows platelet
recruitment (34). The anti-DD3 moAb 418 cross-competed with the
anti-A1 domainmoAbs 701 and 724whenVWFwas in solution, but not
on immobilized VWF, indeed providing evidence for a changing dis-
tance between the domains upon immobilization. Previous studies sug-
gested a structural change in the DD3 region upon immobilization of
VWF onto calf skin collagen, causing a reduced affinity for factor VIII
(43). It could be that similar conformational changes in the DD3 region
are induced by immobilization of VWFon a polystyrene surface, leading
to disruption of the structural proximity of this region with the A1
domain, thereby exposing the GPIb binding site.
Finally, we also found a striking sequence similarity between the pri-
mary sequence of the complimentarity determining region 3 of the
1C1E7 heavy chain and the N-terminal flanking region of the VWF A1
domain (aa 1260–1271). This N-terminal flanking region is important
in modulating the binding of the A1 domain with GPIb as modifica-
tions or deletions in this region increase the affinity of VWF for GPIb
(14, 38), and in our view this might be the region within the A1 domain
that interacts with the DD3 region. 1C1E7 then would compete with
this N-terminal flanking region disrupting this interaction. Because
1C1E7 interacts with K968 in the D3 domain, it is possible that the
N-terminal flanking region interacts with this residue as well.
In conclusion, our results demonstrate an inhibitory role for the aa
764–1035 region in VWF for the GPIb interaction. Based on these
observations, the following hypothesis might be put forward. In native,
resting conditions, the A1 domain and the DD3 region are in close
proximity, possibly through an interaction of the N-terminal flanking
region of the A1 domain with the D3-domain, more precisely with the
region of residue Lys-968. This interaction would limit the accessibility
of theGPIb binding site.WhenVWF is immobilized, this interaction is
disrupted through conformational changes in VWF, possibly in the
DD3 region which allows recruitment of platelets through their GPIb-
IX-V complex. Further studies are required to confirm this hypothesis.
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